Wegovy 0.5mg Results: What Actually Happens at This Dose

Four weeks in, wondering if it's working, this is where most people are

You've had the first pen at 0.25mg. The dose has now stepped up to 0.5mg, and maybe the scales have barely moved. A question our prescribers hear regularly at this stage is: "Should I be seeing more by now?" It is a completely fair thing to wonder, especially when the figures cited online (15%, 20% weight reduction) sound so significant.

Here is the thing that often gets lost: those figures are endpoint results, measured after 68 weeks at the 2.4mg maintenance dose in the STEP 1 trial. The 0.5mg phase is not the place where the trial's headline outcome was generated. It is the second rung of a deliberate titration schedule designed to reduce the chance of side effects, not to deliver maximum efficacy. The body needs time to adapt to semaglutide's GLP-1 receptor activity, and the dose escalation gives it that time. Early changes in appetite (a slightly smaller plate, feeling full faster) are often the first signal that the medicine is active, even when the number on the scales has not shifted dramatically yet. If you want a clearer sense of how the full titration journey unfolds, the Wegovy dosing schedule overview sets it out step by step.

Some people do lose a meaningful amount of weight at 0.5mg. Others see very little. Both experiences sit within the normal range for this stage.

What the evidence says (and what it does not say) about early-phase results

The STEP 1 trial, published in the New England Journal of Medicine, remains the largest body of phase-3 evidence for semaglutide 2.4mg in weight management. Participants achieved around 15% average body-weight reduction over 68 weeks. The trial was not designed to isolate 0.5mg results specifically (participants moved through the titration steps as a continuous treatment arc) so there is no clean, published figure for "weight lost at exactly 0.5mg" that can be quoted with precision. That gap in the literature is itself useful information.

What the trial structure does tell us is that weight loss tends to be gradual and cumulative across the full dose escalation. The steeper reductions typically emerge at 1.7mg and 2.4mg, once appetite suppression has built over several months. A common misconception is that if you are not losing weight quickly at 0.5mg, the medicine is not working for you personally. The evidence does not support that conclusion; early tolerance-building is part of how the medicine is designed to be taken. The results at the 2.4mg maintenance dose give a better benchmark for what the full course aims toward.

NICE's appraisal of semaglutide for weight management (TA875) is based on the full treatment course, further reinforcing that the medicine is evaluated as a programme rather than a snapshot at any single dose.

Side effects at 0.5mg: what is typical, and when to pay attention

The step up to 0.5mg is often where GI effects become more noticeable. Nausea is the most commonly reported experience; loose stools, constipation, reflux, and a general feeling of fullness after eating less than usual are also frequently mentioned. For most people these effects peak in the first week or two after a dose step and then ease as the body adjusts. They are not a sign that something is wrong. Eating smaller portions, avoiding high-fat meals, and staying well hydrated all tend to help.

Some effects warrant prompt medical attention. Severe stomach pain that radiates through to the back (particularly if accompanied by vomiting) should be assessed by a doctor straight away, as pancreatitis, though infrequent, is a known risk with GLP-1 medicines. The full Wegovy information page covers the side-effect profile in more detail, and the NHS patient information for semaglutide is worth reading alongside your Patient Information Leaflet. Side effects can be reported through the MHRA's Yellow Card scheme.

Pregnancy, breastfeeding, and trying to conceive are all circumstances where semaglutide is not recommended. Under-18s are outside the licensed age range. A prescriber will have covered these points during your consultation, but they are worth revisiting if your circumstances change.

Moving beyond 0.5mg: what the next steps look like

If 0.5mg is tolerated well after four weeks, the schedule moves to 1.0mg, and results often begin to feel more tangible from that point onward. The appetite suppression typically deepens with each step. The 1mg Wegovy results page explains what shifts at that stage, and the 1.7mg phase sits just beyond it.

Timing of dose changes is a clinical decision, not a self-directed one. If side effects at 0.5mg have been significant, a prescriber may recommend staying at this dose for longer before increasing. If you started on Wegovy through a private service and have questions about your next step, your prescribing team is the right first call. For people weighing up whether to begin treatment, the treatment consultation page outlines the full process. The starting 0.25mg phase is covered separately if you want to understand the baseline before 0.5mg. Cost context for private treatment is covered on the Wegovy access page.

Lifestyle factors sit alongside the medicine throughout. Clinical trials require participants to maintain a reduced-calorie diet and increase physical activity, the trial figures reflect both the drug effect and those behavioural elements together. The NHS's Better Health: Lose Weight resource offers practical guidance on building those habits in parallel with treatment.